Bictegravir/emtricitabine/tenofovir alafenamide in patients with genotypic NRTI resistance
Sign Up to like & getrecommendations! Published in 2022 at "HIV Medicine"
DOI: 10.1111/hiv.13376
Abstract: Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) is approved for treatment of HIV without known resistance to its components. Several studies have demonstrated efficacy of B/F/TAF in patients with nucleoside reverse transcriptase inhibitor (NRTI) resistance‐associated mutations (RAMs), mainly identified… read more here.
Keywords: emtricitabine tenofovir; nrti resistance; bictegravir emtricitabine; resistance ... See more keywords